Gebasaxturev

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameGebasaxturev
Drug Alias NameCoxsackievirus A21 (Viralytics)CavatakV-937CVA-21
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionComplement decay-accelerating factor inhibitorsIntercellular adhesion molecule-1 inhibitors
TargetsComplement decay-accelerating factorIntercellular adhesion molecule-1
Therapy Area/IndicationsNeoplasm MetastasisUrinary Bladder NeoplasmsProstatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[20] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesViralytics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme LLC
Inactive CompaniesViralytics Ltd
Active IndicationsMelanoma
Inactive IndicationsNeoplasm MetastasisUrinary Bladder NeoplasmsProstatic Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A